CVS Health is pulling from its shelves some cough-and-cold treatments that contain an ingredient that has been deemed ineffective by doctors and researchers.
The drug store chain said it will remove a small number of oral decongestants that contain phenylephrine as the only active ingredient. CVS also said it will still sell “many other oral cough and cold products to meet consumer needs.”
A company spokeswoman declined to elaborate on how many products will be removed when contacted by The Associated Press Friday morning.
CVS Health runs more than 9,000 stores in the United States. Representatives of its national rival, Walgreens, has not pulled any products.
A Walgreens spokeswoman said the company is monitoring the situation and partnering with its clinical integrity office and suppliers “on appropriate next steps.”
U.S. Food and Drug Administration advisers voted unanimously last month against the effectiveness of phenylephrine, which is found in popular versions of Sudafed, Dayquil and other medications stocked on store shelves.
The FDA had asked its outside advisers to examine the long-questioned drug ingredient. Studies conducted in the past few years by the drugmakers Merck and Johnson & Johnson have shown no difference between phenylephrine medications and placebos for relieving congestion.
The FDA, which has not acted on the recommendation of its advisers, said the drug appears more effective when applied directly to the nose, in sprays or drops. Those products are not under review.
Phenylephrine had become the main drug in over-the-counter decongestants when medicines with an older ingredient — pseudoephedrine — were moved behind pharmacy counters. A 2006 law had forced the move because pseudoephedrine can be illegally processed into methamphetamine.
Those original versions of Sudafed and other medicines remain available without a prescription.
The CVS Health announcement comes shortly before another cold-and-flu season starts in the United States as winter sets in. Last year, an unusually fast start to the season led to shortages of Children’s Tylenol and other medications customers can purchase over-the-counter, or without a prescription.
Chipmaker Nvidia is poised to release a quarterly report that could provide a better sense of whether the stock market has been riding an overhyped artificial intelligence bubble or is being propelled by a technological boom that’s still gathering momentum.
Cracker Barrel said late Tuesday it’s returning to its old logo after critics — including President Donald Trump — protested the company’s plan to modernize.
Low-value imports are losing their duty-free status in the U.S. this week as part of President Donald Trump's agenda for making the nation less dependent on foreign goods. A widely used customs exemption for international shipments worth $800 or less is set to end starting on Friday. Trump already ended the “de minimis” rule for inexpensive items sent from China and Hong Kong, but having to pay import taxes on small parcels from everywhere else likely will be a big change for some small businesses and online shoppers. Purchases that previously entered the U.S. without needing to clear customs will be subject to the origin country’s tariff rate, which can range from 10% to 50%.
Southwest Airlines will soon require plus-size travelers to pay for an extra seat in advance if they can't fit within the armrests of one seat. This change is part of several updates the airline is making. The new rule starts on Jan. 27, the same day Southwest begins assigning seats. Currently, plus-size passengers can pay for an extra seat in advance and later get a refund, or request a free extra seat at the airport. Under the new policy, refunds are still possible but not guaranteed. Southwest said in a statement it is updating policies to prepare for assigned seating next year.
Cracker Barrel is sticking with its new logo. For now. But the chain is also apologizing to fans who were angered when the change was announced last week.
Elon Musk on Monday targeted Apple and OpenAI in an antitrust lawsuit alleging that the iPhone maker and the ChatGPT maker are teaming up to thwart competition in artificial intelligence.
Hear from Gabino & Stephen Roche on Saphyre’s institutional AI platform that centralizes pre‑ and post‑trade data, redefining settlement speed and accuracy.
